Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8791 to 8805 of 8885 results

  1. NICE ready to work with company to address uncertainty in evidence for elacestrant for advanced breast cancer

    Today (1 October 2024) NICE is consulting on draft guidance that does not recommend elacestrant for treating a type of advanced breast cancer.

  2. NICE Board says new method allowing greater weight to be given to severe diseases is working

    At today's meeting (25th September 2024) our board has concluded that the new severity modifier is working as intended.

  3. Adults with Von Hippel-Lindau disease to benefit from new treatment

    NICE has recommended belzutifan for some adults with Von Hippel-Lindau disease, in final draft guidance, which could benefit up to 100 people.

  4. Thousands could benefit from new option for treating symptoms of uterine fibroids

    As many as 30,000 adults could benefit from a new treatment for moderate to severe symptoms of uterine fibroids after we published final guidance today (14 August 2024) recommending linzagolix.

  5. World's first gene editing therapy for blood disorder to be available to hundreds of patients in England

    Patients in England with severe beta-thalassaemia will be amongst the first in Europe to benefit from one-time gene therapy exagamglogene autotemcel.

  6. 14,000 women at risk of fractures after the menopause to benefit from bone disease drug

    Over 14,000 people to benefit after NICE published final guidance recommending abaloparatide as an option for treating osteoporosis after menopause, if there is a very high risk of fracture.

  7. NICE disappointed companies unwilling to offer fair price to make Enhertu available for advanced breast cancer

    Daiichi Sankyo and partner company AstraZeneca have been unwilling to offer a price that would enable NICE to recommend Enhertu as cost effective for the NHS in final guidance published today.

  8. New joint guideline recommends prescribing combination treatments for people with newly diagnosed asthma

    For the first time, the British Thoracic Society (BTS), National Institute for Health and Care Excellence (NICE) and the Scottish Intercollegiate Guidelines Network (SIGN) have collaborated to develop a UK-wide asthma guideline.

  9. NICE responds to failure of talks to reach price agreement on Enhertu

    Talks with the makers of Enhertu have ended without agreement, meaning guidance that does not recommend Enhertu for advanced breast cancer will remain unchanged.

  10. Keep the size of your waist to less than half of your height, NICE recommends

    People are being encouraged to keep their waist measurement to less than half their height to reduce the risk of potential health problems.

  11. People who have had a stroke should be offered additional rehabilitation

    People who have had a stroke and who have continuing impairment or limitations on their activities should be offered additional rehabilitation to help them recover

  12. Three treatments for COVID-19 recommended in final draft guidance

    Everyone with COVID-19 at highest risk of developing severe disease will have access to clinically and cost-effective treatments.

  13. NICE signs up to join the GetReal Institute

    NICE and the GetReal Institute: facilitating the adoption and implementation of real-world evidence in health care decision-making.

  14. Updated guideline recommends more treatment choices for menopause symptoms

    New evidence shows that cognitive behavioural therapy (CBT) can help reduce menopause symptoms including hot flushes and night sweats, depressive symptoms and problems sleeping NICE has said in its draft updated guideline on menopause published today (17 November 2023).

  15. New life-extending drug treatment for children and teenagers with an aggressive form of brain cancer

    Dabrafenib with trametinib is a targeted treatment that can be taken at home rather than hospital and improves the length and quality of life for patients..